Barboval 30 Capsules

$18.00

Barboval 30 Capsules

Produced in Ukraine

Free shipping

Description

Pharmacotherapeutic group:
Sleeping pills and sedatives. Combined preparations of barbiturates. ATX code N05C B02.
Composition:
active ingredients: ethyl ester of α-bromisovaleric acid, menthol solution in menthol ester of isovaleric acid, phenobarbital; 1 capsule contains: ethyl ester of α-bromisovaleric acid – 10 mg, menthol solution in menthol ester of isovaleric acid – 46 mg, phenobarbital – 9.8 mg; excipients: castor oil, lactose monohydrate (200), microcrystalline cellulose 102, crospovidone, calcium stearate, colloidal anhydrous silicon dioxide.
Indications:
Neuroses, accompanied by increased excitability, insomnia, hysteria;
as part of the complex treatment of mild angina attacks, arterial hypertension in the initial stage, tachycardia of functional genesis, with spasms of the stomach and intestines, flatulence.
Contraindications:
Hypersensitivity to any of the drug’s components, hepatic and renal failure, hepatic porphyria, severe arterial hypotension, acute myocardial infarction, diabetes mellitus, depression, myasthenia gravis, alcoholism, drug and drug dependence, respiratory diseases with shortness of breath, obstructive syndrome. The drug is not used for children, pregnant women and women who are breastfeeding.
Method of administration and dosage:
Barboval taken orally. Usually, adults should take 1-2 capsules 2-3 times a day for 10-15 days. It is better to take the drug 20-30 minutes before meals. After a break of 10-15 days, the course of treatment can be repeated. The maximum daily dose is 6 capsules.
Pharmacodynamics:
Barboval is a combined drug, the therapeutic effect of which is due to the pharmacological properties of its components.
Ethyl ester of α-bromisovaleric acid has a reflex, sedative and antispasmodic effect due to a decrease in reflex excitability in the central parts of the nervous system and an increase in inhibition processes in neurons of the cortex and subcortical structures of the brain, as well as a decrease in the activity of the central vasomotor centers and a local direct spasmolytic effect on smooth musculature.
Phenobarbital suppresses the activating effect of the centers of the reticular formation of the middle and medulla oblongata on the cerebral cortex, thereby reducing the flux of excitatory influences on the cerebral cortex and subcortical structures. A decrease in the activating effects reveals, depending on the dose, a sedative, tranquilizing and hypnotic effect.
Barboval reduces the stimulating effects on the vasomotor centers, coronary and peripheral vessels, lowering the total blood pressure, eliminating and preventing vasospasm, especially of the heart.
Menthol in menthol ester of isovaleric acid has a calming effect on the central nervous system, slows down the peristalsis of the stomach and intestines, reduces flatulence, and also has a moderate reflex vasodilator and antispasmodic effect.
Application features:
The presence of phenobarbital in the composition of the drug can lead to the risk of developing Stevens-Johnson and Lyell’s syndrome, which is most likely in the first weeks of treatment. Long-term use is not recommended due to the risk of drug dependence, the possible accumulation of bromine in the body and the development of bromine poisoning.
In cases where pain in the region of the heart does not go away after taking the drug, it is necessary to consult a doctor to exclude acute coronary syndrome. It should be carefully prescribed for decompensated heart failure, arterial hypotension, hyperkinesis, hyperthyroidism, adrenal hypofunction, acute and persistent pain, acute drug intoxication.
Castor oil, which is part of the drug, can cause indigestion and diarrhea. The drug contains lactose, therefore, patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome should not use the drug.
The ability to influence the reaction rate when driving or operating machinery:
Barboval can cause drowsiness and dizziness, therefore, during the period of treatment, patients are not recommended to work with dangerous mechanisms and drive vehicles.
Shelf life: 1 year 6 months.
Do not use the drug after the expiration date printed on the package.
Storage conditions:
Store at a temperature not exceeding 25 ºС. Keep out of the reach of children.
Produced in Ukraine